Krystal Biotech (KRYS) EBIT Margin (2023 - 2026)
Krystal Biotech (KRYS) reported EBIT Margin of 46.12% for Q1 2026, up 501.0% on a YoY basis from 7.67% in Q1 2025, and up 11.59% sequentially from 41.33% in Q4 2025.
Krystal Biotech (KRYS) EBIT Margin (2023 - 2026) Analysis & Trends
Krystal Biotech (KRYS) has 4 years of EBIT Margin data on file, last reported at 46.12% in Q1 2026.
- For the quarter ending Q1 2026, EBIT Margin rose 501.0% year-over-year to 46.12%; the trailing twelve-month figure through Mar 2026 stood at 42.8% (up 1022.0% YoY), and the FY2025 full-year result was 41.45%, up 1882.0% from the prior year.
- EBIT Margin improved to 46.12% in Q1 2026, from 41.33% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 46.12% in Q1 2026 to a low of 303.8% in Q3 2023.
- A 4-year average of 1.33% and a median of 40.93% in 2025 frame the typical range for EBIT Margin.
- Across the five-year window, EBIT Margin surged 33060 bps in 2024 and tumbled 406 bps in 2025, its largest moves.
- Tracing KRYS's EBIT Margin over 4 years: stood at 7.71% in 2023, then jumped by 489 bps to 45.4% in 2024, then fell by 9 bps to 41.33% in 2025, then advanced by 12 bps to 46.12% in 2026.
- Business Quant data shows KRYS's EBIT Margin at 46.12% in Q1 2026, 41.33% in Q4 2025, and 42.3% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 16.51% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 30.35% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Krystal Biotech | 9.84 Bn | 9.02 Bn | 110.08 Mn | 46.12% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 46.12% |
| Dec 31, 2025 | 41.33% |
| Sep 30, 2025 | 42.30% |
| Jun 30, 2025 | 40.93% |
| Mar 31, 2025 | 41.11% |
| Dec 31, 2024 | 45.40% |
| Sep 30, 2024 | 26.80% |
| Jun 30, 2024 | 12.18% |
| Mar 31, 2024 | -14.77% |
| Dec 31, 2023 | 7.71% |
| Sep 30, 2023 | -303.80% |